. . . Shops Leiner, Sterigenics Deals

UBS is also launching deals this week for Leiner Health Products and Sterigenics International.

  • 30 Apr 2004
Email a colleague
Request a PDF

UBS is also launching deals this week for Leiner Health Products and Sterigenics International. The Leiner facility, led by UBS, Morgan Stanley and Credit Suisse First Boston, is made up of a five-year, $50 million revolver and seven-year, $240 million term loan. The Sterigenics deal comprises a $35 million revolver, $170.5 million term loan and $35 million second-lien term loan. Price talk on the first- and second-lien term loans is LIBOR plus 3% and 6 1/4%, respectively. Ballpark pricing on the revolver was not available. The Leiner credit backs a $650 million recapitalization of the vitamin maker by North Castle Partners and Golden Gate Capital. The Sterigenics deal backs PPM Ventures' and PPM America Capital Partners' acquisition of the sterilization and ionization business of Ion Beam Applications. A PPM official declined comment.

  • 30 Apr 2004

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Bank of America Merrill Lynch (BAML) 3,319 10 12.84
2 Citi 2,562 6 9.92
3 Goldman Sachs 2,150 3 8.32
4 Credit Suisse 1,822 6 7.05
5 Societe Generale 1,814 4 7.02

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 22 May 2017
1 Citi 41,255.30 117 12.99%
2 Bank of America Merrill Lynch 37,631.92 109 11.85%
3 Wells Fargo Securities 32,082.26 89 10.11%
4 JPMorgan 20,969.41 64 6.60%
5 Credit Suisse 16,754.47 44 5.28%